What is the Return on Assets (ROA) of Cyclopharm this year?
The Return on Assets (ROA) of Cyclopharm is -0.21 undefined this year.
Cyclopharm ROA 2025
Cyclopharm ROA
-0.21
Ticker
CYC.AX
ISIN
AU000000CYC5
In 2025, Cyclopharm's return on assets (ROA) was -0.21, a 107.49% increase from the -0.1 ROA in the previous year.
Cyclopharm Aktienanalyse
What does Cyclopharm do?
Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Cyclopharm's Return on Assets (ROA)
Cyclopharm's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Cyclopharm's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Cyclopharm's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Cyclopharm’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Cyclopharm stock
What was the ROA of Cyclopharm compared to the previous year?
The ROA of Cyclopharm has increased by 107.49% compared to the previous year.
What consequences do high ROA have for investors of Cyclopharm?
A high ROA is advantageous for investors of Cyclopharm, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Cyclopharm?
A low ROA can be unfavorable for investors of Cyclopharm as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Cyclopharm affect the company?
An increase in ROA of Cyclopharm can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Cyclopharm impact the company?
A reduction in the ROA of Cyclopharm can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Cyclopharm?
Some factors that can influence the ROA of Cyclopharm include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Cyclopharm important for investors?
The ROA of Cyclopharm is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Cyclopharm take to improve ROA?
To improve ROA, Cyclopharm can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Cyclopharm pay?
Over the past 12 months, Cyclopharm paid a dividend of 0.01 AUD . This corresponds to a dividend yield of about 1.06 %. For the coming 12 months, Cyclopharm is expected to pay a dividend of 0.05 AUD.
What is the dividend yield of Cyclopharm?
The current dividend yield of Cyclopharm is 1.06 %.
When does Cyclopharm pay dividends?
Cyclopharm pays a quarterly dividend. This is distributed in the months of May, October, April, October.
How secure is the dividend of Cyclopharm?
Cyclopharm paid dividends every year for the past 3 years.
What is the dividend of Cyclopharm?
For the upcoming 12 months, dividends amounting to 0.05 AUD are expected. This corresponds to a dividend yield of 5.59 %.
In which sector is Cyclopharm located?
Cyclopharm is assigned to the 'Health' sector.
Wann musste ich die Aktien von Cyclopharm kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Cyclopharm from 9/11/2023 amounting to 0.005 AUD, you needed to have the stock in your portfolio before the ex-date on 9/1/2023.
When did Cyclopharm pay the last dividend?
The last dividend was paid out on 9/11/2023.
What was the dividend of Cyclopharm in the year 2024?
In the year 2024, Cyclopharm distributed 0.01 AUD as dividends.
In which currency does Cyclopharm pay out the dividend?
The dividends of Cyclopharm are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Cyclopharm
Our stock analysis for Cyclopharm Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cyclopharm Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
